AAV基因治疗再给药治疗OTOF相关耳聋的单臂试验
针对OTOF相关耳聋患者,在AAV1-hOTOF单次给药后存在中和抗体的情况下,对侧耳二次给药。4例患者(2.2-3.4岁)随访26-52周,6周内无剂量限制性毒性,26周听性脑干反应阈值从基线>95 dB改善至43、63、80和53 dB,不良事件多为1-2级。
要点
- AAV1-hOTOF对侧耳再给药在已有中和抗体的患者中未出现剂量限制性毒性。
- 再给药后26周听性脑干反应阈值较基线>95 dB明显改善。
- 安全性以1-2级不良事件为主,无严重不良事件。
核心结论
- AAV1-hOTOF基因治疗对侧耳再给药在OTOF相关耳聋患者中显示初步安全性和听力改善效果。
研究设计与样本
- 单臂试验,纳入4例既往接受单次AAV1-hOTOF基因治疗、年龄2.2-3.4岁、存在中和抗体(滴度1:135-1:3,645)的OTOF相关耳聋患者,对侧耳二次给药,随访26-52周。
主要发现
- 6周内无剂量限制性毒性发生。
- 再治疗耳26周平均听性脑干反应阈值从基线>95 dB分别改善至43 dB、63 dB、80 dB和53 dB(患者1-4)。
- 所有不良事件为1-2级,除1例3级中性粒细胞计数降低;无严重不良事件。
关键数值与推荐
- 主要终点:6周内剂量限制性毒性发生率,结果为无剂量限制性毒性。
- 次要终点包括安全性和听觉功能;26周平均听性脑干反应阈值患者1-4分别为43 dB、63 dB、80 dB和53 dB。
- 中和抗体滴度范围1:135-1:3,645。
临床怎么用
- 对已接受AAV1-hOTOF单次治疗且存在中和抗体的患者,对侧耳再给药可能改善听力且安全性可接受。
- 再给药后需监测不良事件,尤其是中性粒细胞计数。
局限性
- 样本量小(4例),随访时间有限(26-52周)。
- 需更长随访和更大队列验证重复给药的安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Re-administration of adeno-associated virus (AAV)-mediated gene therapy remains challenging due to neutralizing antibodies (NAbs) induced by the initial dose. We previously conducted a single-arm trial showing that single-dose administration of AAV-hOTOF gene therapy in individuals with OTOF-related deafness is safe and leads to hearing improvements. Here we initially demonstrate that AAV1-hOTOF re-administration to the contralateral ear in Otof-/- mice with peak serum NAb titers successfully rescued hearing with limited immune activation. After a protocol amendment of our trial, four patients (aged 2.2-3.4 years) with pre-existing NAbs (titers 1:135-1:3,645), who had previously received a single dose of the gene therapy, were enrolled to receive a second dose in the contralateral ear, as part of the ongoing trial, with a follow-up ranging from 26 weeks to 52 weeks. The primary endpoint was the occurrence of dose-limiting toxicities at 6 weeks and secondary endpoints included safety and auditory function. No dose-limiting toxicity occurred within 6 weeks. In the secondary outcomes, the 26-week average auditory brainstem response threshold in the second treated ear improved from >95 dB at baseline to 43 dB, 63 dB, 80 dB and 53 dB in patients 1-4, respectively. Safety assessment showed that all adverse events were grade 1-2, except one grade 3 decreased neutrophil count; no serious adverse events occurred. These data provide preliminary insights on the safety and efficacy of re-administration of AAV1-hOTOF gene therapy in patients with congenital deafness. Longer follow-up and larger cohorts are needed to establish the safety and efficacy of repeated administration of gene therapies. Trial registration no.: ChiCTR2200063181 .
引用
- Fan X, Zhang L, Gao Z, et al. Re-administration of AAV-mediated gene therapy for OTOF-related deafness: a single-arm trial. Nat Med. 2026. PMID: 42362868. doi:10.1038/s41591-026-04505-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。